AI-BASED PRECISION DIAGNOSTICS TO IMPROVE CANCER TREATMENT DECISIONS AND PATIENT OUTCOMES
A CE-IVD solution for prognostic risk profiling of invasive breast cancer, the first-in-class.
Stratipath Breast validated in large independent studies
Stratipath is leveraging state-of-the-art deep learning technologies (AI) to provide risk profiling of cancer tumours.
Follow the news about Stratipath.
Join our mission to improve patient outcomes.
Co-founder and professor of pathology, Johan Hartman, explains Stratipath in this 3 min video.
Stratipath is an AI company dedicated to revolutionising cancer treatment decisions and improving patient outcomes by assisting physicians in delivering optimal treatment to every patient.
Stratipath’s pioneering solutions and AI-based precision diagnostic software platform transform tissue sample analysis, enabling breakthrough insights for enhanced and faster patient stratification across healthcare, clinical trials, and drug development.
By expanding the reach of precision medicine, Stratipath aims to make this advanced healthcare approach accessible to a wider patient population. Founded as a spin-out of Karolinska Institutet in Stockholm, Sweden, Stratipath is built upon years of groundbreaking research and development.
Stratipath Breast is the first AI-based prognostic risk profiling tool, regulatory aligned for clinical use in the EU and the UK. The solution analyses cancer tissue, enabling the identification of patients with either an increased, or low, risk of disease progression. It is already in clinical use and validated in large-scale studies, ensuring robust and reliable performance.
“Stratipath Breast offers a faster and more cost-effective alternative to gene expression tests, allowing more patients to have access to precision diagnostics.”
Johan Hartman
Professor of pathology at Karolinska Institutet, Stockholm and co-founder of Stratipath.
A paradigm shift in prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays.
For commercial rollout, distribution and optimal clinical workflow. SaaS solution integrated with leading digital pathology solutions.
In healthcare – oncology clinics and pathology labs.
AI platform enabling rapid development, validation and deployment of AI-based precision diagnostics.
Published in high-impact journals and ongoing studies to support current and future solutions.
A paradigm shift in prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays.
For commercial rollout, distribution and optimal clinical workflow. SaaS solution integrated with leading digital pathology solutions.
In healthcare – oncology clinics and pathology labs.
AI platform enabling rapid development, validation and deployment of AI-based precision diagnostics.
Published in high-impact journals and ongoing studies to support current and future solutions.
